targets and antibody effector mechanisms
Different antigens can be the target of MoAbs in leukaemias and lymphomas. In Table 1 , some of the antigens potentially interesting in clinical practice are listed. The list is not complete because the number of possibilities is large. The optimal target for MoAb therapy would be a specific antigen present at high density on tumour cells, absent or present at low concentrations on normal cells (or present in non-critical host cells), with stable expression and with no modulation or internalization. CD20 antigen, present in most B-cell neoplasias, has all of these requisites and is the paradigm of the target molecules [6, 12, 13] . Nevertheless, even in those cases with a lack of high tumour specificity, MoAbs offer the possibility of lower toxicity, compared with conventional chemotherapies, by increasing the therapeutic index and with no overlapping toxicity with the standard drugs [6] .
Native unconjugated antibodies were the first ones used in clinical practice. The mechanisms of action to kill the tumour cells include complement-dependent cytotoxicity (CDC) (affected by antibody isotype and species, and antigen density), antibody-dependent cellular cytotoxicity (ADCC) [which requires specific isotypes and adequate ratios of effector cells, including natural killer (NK) cells, macrophages and polymorphonuclear cells, to target cells] and receptor-based signalling [12] [13] [14] [15] [16] [17] . In addition, certain characteristics of the antibodies may modulate their activity. Thus, a humanized (at least chimeric) MoAb will have less immune response from the host by not producing inactivating antibodies. More recently, in order to increase the anti-tumour effect, MoAbs have been conjugated either with radiation emitters or with cytotoxins [18] [19] [20] [21] . The latter could substantially increase the cytotoxic capability, but also the toxicity for the patient. Radio-immunotherapy with beta-emitting isotopes, such 131 I or 90 Y, has the advantage of making a 'crossfire effect' eliminating tumour cells to which the MoAb is not directly bound, although of course, the dose-limiting toxicity to normal cells is important [10, 21] . Cytotoxins conjugated to MoAb, such as calicheamicin (anti-tumour antibiotic), or toxins such as ribosomal inhibitory proteins (e.g. ricin, gelonin) are drugs that require entry to the cell to work, but once inside are extremely toxic for tumour cells.
Another aspect to point out regarding the treatment with MoAb is the possibility of additive or synergistic effect with some of the standard chemotherapies [22, 23] . This is important since the synergistic effect could be obtained with no substantial increase in toxicity. The advances during the last years in immunotherapy of haematological malignancies derive from the combination of MoAbs with conventional chemotherapy.
lymphoproliferative disorders rituximab
Rituximab is a chimeric monoclonal immunoglobulin G1 antibody of humanized murine origin and targets the cell surface receptor CD20. It was the first antibody widely used in patients with malignant and non-malignant diseases. In the lymphoma setting, since its first use in humans a decade ago, rituximab has become an essential component of the therapy in all types of B-cell lymphomas, probably representing the major advance in this field since the use of doxorubicin in the 1970s [1, 3, 4] . Alone or in combination with chemotherapy, rituximab has dramatically improved the prognosis of patients with indolent and aggressive lymphomas.
The murine portion of the antibody, the Fab variable region, binds CD20 on the surface of the lymphoma cells with a high degree of specificity. The human portion of the antibody, the Fc region of the IgG1 immunoglobulin isotype, is then responsible for stimulating the immune pathways of the patient. The mechanisms of action, although not completely understood, include CDC, ADCC and receptor-based signalling, and, as already mentioned, rituximab shows synergy with other drugs [12, 17, 22, 23] . The appearance of inactivating antibodies against rituximab is rare and does not represent a problem in clinical practice.
The regimen of administration of rituximab is indicated in Table 2 .
The main side effect is the infusion syndrome, seen during or in the next few hours after infusion, particularly during the first administration. It includes fever, chills, dizziness, nausea, itching, swelling of the throat, cough, fatigue, hypotension or transient bronchospasm [24] [25] [26] . The most severe form of presentation is the 'cytokine release syndrome', observed in patients with circulating malignant cells [27] . The severity of the syndrome directly depends on the number of circulating cells. Nevertheless, this complication is the exception and, in general, the infusion syndrome, if present, is mild and does not appear in the following infusions.
Another common toxicity is the depletion of normal CD20-positive lymphocytes from the blood, bone marrow and lymph nodes. However, at least for standard doses, this depletion does not compromise immunity: immunoglobulin levels do not significantly vary and there is no increased risk for infections, with the exception of some viruses like herpes virus, cytomegalovirus and hepatitis B virus. The toxicity in long-term treatment with rituximab (for instance, in the maintenance setting) is still under investigation.
CD20 is present in most B-cell lymphoproliferative disorders. Rituximab was first designed for indolent lymphomas {mainly follicular lymphoma (FL) [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] }, but its use has been progressively expanded to all B-cell CD20-positive malignancies, including diffuse large B-cell lymphomas (DLBCL) [39] [40] [41] [42] [43] [44] , mantle-cell lymphomas [35, 45, 46] , MALT lymphomas [47] , Waldenström disease, chronic lymphocytic leukaemia (CLL) [48] [49] [50] [51] [52] [53] [54] , some types of Hodgkin's lymphomas, and also to some T-cell tumours such angioimmunoblastic lymphoma. follicular lymphoma (FL). Rituximab was first assayed as monotherapy in FL. In the pivotal study performed in previously treated patients with low-grade lymphomas (mostly FL) [28] , a response rate of 48% was observed, including 6% of complete response (CR). The response duration lasted for a median of 12 months. Patients relapsing after rituximab were re-treated with the same drug with similar responses and a few side effects. For untreated low-risk FL, the response rate with rituximab was 73%, including 26% of CRs and a proportion of molecular responses [31] . About 20% of responders maintained the response 7 years after rituximab [55] . Thus, single agent rituximab is at least as good as the majority of chemotherapies in this setting.
The combination of rituximab plus standard chemotherapy dramatically increases the CR rate, failure-free and disease-free survival both in previously treated and untreated patients. The latter was observed with different regimens {CVP (cyclophosphamide, vincristine and prednisone) [33] , CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) [34] , FCM (fludarabine, cyclophosphamide and mitoxantrone) [37] or MCP (mitoxantrone, chlorambucil and prednisolone) [35] }. Recent reports have pointed out that patients treated with rituximab containing regimens had better overall survival than those treated without rituximab [33, 34, [56] [57] [58] . In Table 3 , main clinical trials in first-line are detailed. Based on these results, the combination of rituximab plus chemotherapy is considered the standard treatment in patients with FL; however, which chemotherapy regimen is the optimal to combine with rituximab remains controversial. In recent years, data from different institutions suggest a survival improvement in patients with FL, most likely due to the introduction of rituximab.
A new role for rituximab in patients with FL is as maintenance treatment after achieving a response with any rituximab-containing regimen [59] [60] [61] . There are data indicating advantages in terms of survival for patients receiving this maintenance therapy [31] . A multi-centre trial is ongoing to establish the role of maintenance with rituximab in first-line (PRIMA trial).
diffuse large B-cell lymphoma (DLBCL). After the results published by the French group GELA [39, 40] , the new gold-standard in DLBCL is the combination of rituximab plus chemotherapy (CHOP being the most popular regimen). In a series of patients between 60 and 80 years of age diagnosed with DLBCL, R-CHOP demonstrated superiority over CHOP in terms of CR rate, primary resistance, event-free, progression-free, disease-free and overall survival (Table 3) .
This survey was confirmed in a similar group of patients in an American study [42] . Although the design was different (patients in response were randomized to no further treatment or maintenance with rituximab), those patients receiving rituximab either with CHOP or as maintenance had better survival. Moreover, the superiority of R-CHOP was shown in the setting of younger patients with low-risk DLBCL [41] . More recently, the addition of rituximab to a high-density regimen (CHOP-14) has demonstrated an improvement of response, disease-free and overall survival [44] .
There are several ongoing studies on the role of rituximab in combination with other chemotherapy regimens, with autologous stem-cell transplantation, as well as the combination of different MoAbs plus rituximab-containing chemotherapy.
chronic lymphocytic leukaemia (CLL). In patients with CLL, rituximab alone has a discreet effect due, in part, to the low density of CD20 antigen in the surface of CLL tumour cells [13] . Higher doses (500-2250 mg/m 2 ) are necessary to increase the responses [51] . The combination with chemotherapy notably improves the effect of the latter. The combination of rituximab with fludarabine and cyclophosphamide shows a CR rate of about 70%, with a high proportion of patients reaching a molecular CR [52] [53] [54] . Certainly, the toxicity of the combination, especially in terms of immunosuppression, should be taken into account. The use of rituximab in maintenance therapy is currently under investigation. Y that delivers b-radiation in a 1-5 mm radium sphere. The infusion of the radiolabeled MoAb is preceded by two doses of a 'cold' unlabeled anti-CD20 (rituximab). Dosimetry estimation, mandatory for other radioisotopes, seems not to be necessary for [
90 Y]ibritumomab tiuxetan [10] . The main toxicity is myelosuppression, especially when bone marrow is involved by the lymphoma. For this reason, patients with platelet count <100 · 10 9 /l and/or bone marrow involvement >25% should not receive [ 90 Y]ibritumomab tiuxetan. Nadir of neutrophils, haemoglobin and platelets occurs at 5-8 weeks after the dose. It is of note that no strong evidence of higher risk of myelodysplasia or acute leukaemia has been reported and the cases seen were most likely related to previous therapy with alkylating agents or fludarabine-containing regimens.
[ 90 Y]Ibritumomab tiuxetan has shown activity in relapsed FL patients, in whom CR rate and failure-free survival after this drug is longer than after rituximab [62, 63] . Noteworthy is that a proportion of relapsed patients had prolonged CR periods. At the present time, the established indication of this molecule is for relapsed or resistant to rituximab FL. In DLBCL and MCL ]tositumomab has been combined with CHOP as consolidation, with 90% of overall response and 67% CR [64] [65] [66] [67] [68] . Currently there is an ongoing study that compares rituximab and [
131 I]tositumomab combined with CHOP in FL patients not previously treated.
alemtuzumab
Alemtuzumab is a humanized IgG1 monoclonal antibody with specificity for the CD52 antigen, a glycosylphosphatidylinositol-anchored (lymphocyte-surface glycoprotein) which is widely expressed at high density on all human lymphoid cells (except plasma cells), as well as in eosinophils, monocytes, dendritic cells and macrophages.
Alemtuzumab is classically administered in a 2-hour intravenous infusion. Standard dose is 3 mg (1st day), 10 mg (2nd day) and 30 mg (3rd day); if it is well tolerated, 30 mg will be administered 3 days per week for 8-12 weeks. Subcutaneous administration is being increasingly used because the infusion syndrome is less frequent and does not need escalation of the dose. Pre-medication is usually given to prevent side effects of infusion (headache, mouth sores, rash, low blood pressure and fatigue), including dexchlorpheniramine, acetaminophen and hydrocortisone. Immunosuppression is the most important toxic effect, but it is manageable. Prophylaxis against Pneumocystis carinii should be used and prophylaxis against herpes zoster/simplex and fungal infections should also be considered. Weekly monitoring with cytomegalovirus polymerase chain reaction testing is recommended [10] .
At present, alemtuzumab is licensed for patients with CLL, previously treated with alkylating agents and refractory to fludarabine. In this setting, reports shows that up to 87% of previously untreated patients respond to alemtuzumab with a 17% CR. Combination with other drugs, including fludarabine and rituximab, is the subject of in-progress investigations [69] [70] [71] [72] . Strong immunosuppression is the main concern. Some responses have also been attained in refractory T-cell prolymphocytic leukaemia. Moreover, peripheral T-cell lymphomas constitute a group of poor-risk symposium article patients in whom alemtuzumab alone or in combination may have an important role [69, 70] . Lastly, in the setting of allogeneic trasnplantation, alemtuzumab is used in order to do the T-cell depletion.
denileukin diftitox
Denileukin diftitox is a fusion protein that targets the diphtheria toxin to cells expressing the interleukin-2 receptor (CD25). When internalized into the cell, the drug inhibits protein synthesis. This MoAb has been used in cutaneous T-cell lymphoma, refractory B and T-cell lymphomas and in fludarabine-resistant CLL [73] .
other antibodies
Due to the content limitation required for this review it would be impossible to mention many other MoAbs that are being used in clinical trials. However, among these it would be of interest to mention the following molecules: the new different anti-CD20 MoAb (including the fully humanized IMMU-106 hA20), anti-CD22 (unconjugated epratuzumab and calicheamicin conjugated CMC-544), anti-CD30 (SGN-30 and iratumumab), anti-CD40 (SGN-40), anti-CD80 (galiximab), anti-CD2 (siplizumab) and anti-CD4 (L3T4). Bevacizumab, a VEGF (vascular endothelial growth factor) inhibitor may play also an interesting anti-lymphoma role in the future.
acute leukaemias Table 1 shows a list of potential targets to block by MoAb in acute leukaemias. Gemtuzumab ozogamicin is nowadays the only one being used in the clinical practice out of clinical trials.
gemtuzumab ozogamicin
Gemtuzumab ozogamicin is an immunoconjugate of an anti-CD33 antibody chemically linked to a potent cytotoxic agent, calicheamicin. It appears to be particularly active in patients with acute leukaemia. CD33 antigen is expressed on the surface of leukaemic cell blasts in more than 90% of patients with acute myeloblastic leukaemia [7] . It is administered as a 2-hour intravenous infusion. The dose infused is 6-9 mg/m 2 in two administrations. Side effects include myelosuppression, headache, rash, low blood pressure, increased levels of hepatic enzymes and fatigue. A unique potential toxicity is a venoocclusive-like disease that may be very severe and always problematic in patients who subsequently undergo through haematopoietic stem cell transplantation.
As single agent treatment (9 mg/m 2 in two doses), 26% of patients receiving gemtuzumab ozogamicin reached CR that lasted for a median of 6 months [74] . The feasibility of combining gemtuzumab ozogamicin (at a dose of 3 mg/m 2 ) with chemotherapy has been recently demonstrated with a reasonable toxicity [75] . In this sense, regimens containing thioguanine should be avoided because of grades 3-4 liver toxicity.
conclusion Much progress has been made during the last few decades in the treatment of haematological malignancies. MoAbs represent a major advance towards a targeted therapy that can dramatically improve the anti-tumour effect with a substantial reduction of toxicity derived from therapy. In general, MoAbs are safe, well-tolerated, and have activity in a variety of clinical settings. The combination with chemotherapy as well as the combination of different MoAbs is not a dream for the future, but a solid reality for many patients with lymphoma or leukaemia.
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